RNAi Roundtable: Zilebesiran (ALN-AGT), in Development for the Treatment of Hypertension

RNAi Roundtable: Zilebesiran (ALN-AGT), in Development for the Treatment of Hypertension

On June 30, 2021, we hosted an online RNAi Roundtable to review the progress with zilebesiran (ALN-AGT), an RNAi therapeutic in development for the treatment of hypertension.

Access the replay
View the presentation
Read the transcript

Pushkal Garg, M.D.
Chief Medical Officer

Elizabeth Ofili, M.D., MPH, FACC
Professor of Medicine (Cardiology), Morehouse School of Medicine

Stephen Huang, M.D.
Senior Director, Clinical Research

Eric Green
Senior Vice President, Development Programs



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.